A deep learning model for generating [F]FDG PET Images from early-phase [F]Florbetapir and [F]Flutemetamol PET images.

Journal: European journal of nuclear medicine and molecular imaging
PMID: 38861183

Abstract

INTRODUCTION: Amyloid-β (Aβ) plaques is a significant hallmark of Alzheimer's disease (AD), detectable via amyloid-PET imaging. The Fluorine-18-Fluorodeoxyglucose ([F]FDG) PET scan tracks cerebral glucose metabolism, correlated with synaptic dysfunction and disease progression and is complementary for AD diagnosis. Dual-scan acquisitions of amyloid PET allows the possibility to use early-phase amyloid-PET as a biomarker for neurodegeneration, proven to have a good correlation to [F]FDG PET. The aim of this study was to evaluate the added value of synthesizing the later from the former through deep learning (DL), aiming at reducing the number of PET scans, radiation dose, and discomfort to patients.

Authors

  • Amirhossein Sanaat
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
  • Cecilia Boccalini
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland. cecilia.boccalini@unige.ch.
  • Gregory Mathoux
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
  • Daniela Perani
    Vita-Salute San Raffaele University, Nuclear Medicine Unit San Raffaele Hospital, Milan, Italy.
  • Giovanni B Frisoni
    LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine), IRCCS Centro "S. Giovanni di Dio-F.B.F.", Brescia, Italy; Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
  • Sven Haller
    Department of Surgical Sciences, Radiology, Uppsala University, Sweden.
  • Marie-Louise Montandon
    Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Cristelle Rodriguez
    Division of Institutional Measures, Medical Direction, Geneva University Hospitals, Geneva, Switzerland.
  • Panteleimon Giannakopoulos
    Division of Institutional Measures, Medical Direction, Geneva University Hospitals, Geneva, Switzerland.
  • Valentina Garibotto
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
  • Habib Zaidi
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211, Geneva 4, Switzerland. habib.zaidi@hcuge.ch.

Keywords

External Resources

Popular Topics
Recent Journals